At ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) in Chicago, more than 300 experts will present cutting-edge research and technology that will shape the future of laboratory medicine and improve patient care.
A new study identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy. A secondary finding from the study suggests that the gene signature could potentially also predict whether immunotherapy would help some patients.
The award, $300,000 over the next three years, supports their efforts in gaining a deeper understanding of the microenvironment's role in shaping human glioblastoma, an aggressive type of brain cancer that is fast growing and difficult to treat.
A new study published today in Cancer Discovery is providing insights into why some Merkel cell carcinoma patients respond to this type of immunotherapy while others do not.
According to a July 25 JAMA Oncology review article by experts at Fred Hutch Cancer Center and University of Washington, newly developed national screening guidelines offer hope for identifying the cancer risk of BRCA mutations in men through genetic testing and tailored cancer screening.
The study, published in Urology Practice, reveals that while there were clear differences in treatment preferences among the profiles, these preference profiles did not significantly influence the patients' final treatment choices.
Three junior faculty members at Sylvester Comprehensive Cancer Center have been named K12 2024 Faculty Scholars. The program awards recipients with resources to pursue independent research careers in clinical and translational cancer research.
The results of an international clinical trial led by Michael Birrer, M.D., Ph.D., director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS), on the use of a novel bispecific antibody for women with recurrent or metastatic cervical cancer were published today in JAMA Oncology.
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and preclinical evaluation of the inhibitor, MTX-531 was published in Nature Cancer.
Liver cells have a vital metabolic inflexibility during regeneration to starve dysfunctional cells and keep damage from spreading, according to new research from Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Science.
While chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped. A new project will use AI, in particular, deep reinforcement learning, to analyze multimodal data, and enhance cancer characterization and treatment to ultimately improve patient outcomes. Using personal health data, genetic information about the tumor, and patient treatment and follow-up data, digital twins will simulate diagnoses and treatment options to help physicians choose the most effective treatments and monitor responses over time.
MD Anderson and Summit Therapeutics announced a strategic five-year collaboration to accelerate the development of ivonescimab, a novel PD-1/VEGF bispecific antibody.
Federal health officials recently released new guidelines for anal cancer screening to protect people with HIV, an achievement made possible by a landmark study conducted at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Jackson Memorial Hospital, and other research institutions.
In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
Socioeconomic factors can influence the diagnosis and treatment of children in Texas with malignant solid tumors, increasing the risk of the cancer’s spread and lowering the five-year survival rate, according to researchers at UT Southwestern Medical Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The National Comprehensive Cancer Network (NCCN)’s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
Showing results
1–1 of 1
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
